Phylogeny Report issue

For profit Phase 1
Founded: Columbus OH United States (1997)

Organization Overview

First Clinical Trial
2019
NCT03605719
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Phylogeny

Active Ingredients

Drugs in Phase 1 Trials (4)

carfilzomib (kyprolis) (1 trial)

dexamethasone (1 trial)

nivolumab (opdivo) (1 trial)

pelareorep (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Myeloma (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 4